Methods
409 HIV-positive females across Canada were enrolled in a multi-centered longitudinal cohort study to assess immunogenicity and efficacy of the quadrivalent HPV vaccine. Participant demographic, reproductive, and HIV data was collected. Cervical samples were taken (at 0, 6, 7, 12, 18, 24 months) for cytology (Bethesda System reporting) and HPV DNA typing by Linear array assay.
Methods
409 HIV-positive females across Canada were enrolled in a multi-centered longitudinal cohort study to assess immunogenicity and efficacy of the quadrivalent HPV vaccine. Participant demographic, reproductive, and HIV data was collected. Cervical samples were taken (at 0, 6, 7, 12, 18, 24 months) for cytology (Bethesda System reporting) and HPV DNA typing by Linear array assay.